|
|
|
MIRA INFORM REPORT
|
Report No. : |
511806 |
|
Report Date : |
01.06.2018 |
IDENTIFICATION DETAILS
|
Name : |
CADILA HEALTHCARE LIMITED |
|
|
|
|
Registered
Office : |
‘Zydus Tower’, Satellite Cross Roads, Sarkhej – Gandhinagar
Highway, Ahmedabad – 380015, Gujarat |
|
Tel. No.: |
91-79-26868235 (30 Lines)/ 26868235 |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as
on) : |
31.03.2018 |
|
|
|
|
Date of
Incorporation : |
15.05.1995 |
|
|
|
|
Com. Reg. No.: |
04-025878 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
INR 1024.000 Million |
|
|
|
|
CIN No.: [Company Identification
No.] |
L24230GJ1995PLC025878 |
|
|
|
|
IEC No.: [Import-Export Code No.] |
0895001721 |
|
|
|
|
TIN No.: |
24073801401 |
|
|
|
|
PAN No.: [Permanent Account No.] |
AAACC6253G |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
AHMC00020G |
|
|
|
|
GSTN : [Goods & Service Tax
Registration No.] |
24AAACC6253G1ZZ |
|
|
|
|
Legal Form : |
A Public Limited Liability Company. The Company’s Shares are Listed on
the Stock Exchanges. |
|
|
|
|
Line of Business
: |
Subject operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. (Registered Activity) Line of business is updated as per latest annual report 2017 |
|
|
|
|
No. of Employees
(As on 31.03.2017) : |
16885 (Approximately) Note : As per latest annual report there is an increase in the number of employees over past years and current number employees are 16885 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
A++ |
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
Maximum Credit Limit : |
USD 221300000 |
|
|
|
|
Status : |
Excellent |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Cadila Healthcare Limited operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. Cadila healthcare is one of the top ten players in India.
|
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.09.2017) |
Current Rating (31.12.2017) |
|
India |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
EXTERNAL AGENCY RATING
|
Rating Agency Name |
CRISIL |
|
Rating |
Long term rating : AA+ |
|
Rating Explanation |
High degree of safety and very low credit risk |
|
Date |
13.06.2017 |
|
Rating Agency Name |
CRISIL |
|
Rating |
Short term rating : A1+ |
|
Rating Explanation |
Very strong degree of safety and carry lowest credit risk |
|
Date |
13.06.2017 |
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter in
the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2018.
BIFR (Board for Industrial & Financial Reconstruction) LISTING
STATUS
Subject’s name is not listed as a Sick Unit in
the publicly available BIFR (Board for Industrial & Financial
Reconstruction) list as of 01.06.2018
IBBI (Insolvency and Bankruptcy Board of India) LISTING STATUS
Subject’s name is not listed in the publicly
available IBBI (Insolvency and Bankruptcy Board of India) list as of report
date.
INFORMATION DENIED
Management non-cooperative (Tel. No.: 91-79-26868100/26770100)
LOCATIONS
|
Registered/
Corporate Office : |
‘Zydus Tower’, Satellite Cross Roads, Sarkhej – Gandhinagar Highway, Ahmedabad – 380015, Gujarat, India |
|
Tel. No.: |
91-79-26868235 (30 Lines)/ 26868235 |
|
Fax No.: |
91-79-26732365/ 26732366/ 26862365/ 26862368 |
|
E-Mail : |
investor.grievance@zyduscadila.com
|
|
Website : |
|
|
|
|
|
Formulation Unit: |
|
|
|
|
|
Factory 1 : |
S. No.417, 419 and 420, Sarkhej Bavla National Highway No. 8A, Village Moraiya, Taluka Sanand, District Ahmedabad-382210, Gujarat, India |
|
|
|
|
Factory 2 : |
Plot No.203-213, Kundaim Industrial Estate, Ponda – 403401, Goa, India |
|
|
|
|
Factory 3 : |
Village Saraj Mujra, P. O.– Baddi, Tehsil – Nalagarh, District – Solan - 173205, Himachal Pradesh, India |
|
|
|
|
Topical Plant: |
Plot No. 254/255, Opposite Laxmi Narayan Petrol Pump, Behind Zyfine Chemicals, Sarkhej Bavla, National Highway No. 8A, Changodar Road, Taluka Sanand, District-Ahmedabad - 382 210, Gujarat, India |
|
|
|
|
Biologics Unit: |
Survey No. 40P, 23, 25P, 42, 37, Opposite Ramdev Masala, Sarkhej-Bavla, National Highway No. 8A, Changodar, District - Ahmedabad, Gujarat, India |
|
|
|
|
API Units 1 : |
Block No. 265/266, Village: Changodar Sarkhej Bavla, National Highway No.8A, GIDC Estate, Ankleshwar, Gujarat, India |
|
|
|
|
API Units 2 : |
Dabhasa, Taluka Padra, District Vadodara, Gujarat, India |
|
|
|
|
API Units 3 : |
Block No. 162, Ekalbara Umraya Road, Village Dabhasa, Taluka Padra, District Vadodara, Gujarat, India |
|
|
|
|
API Units 4 : |
Plot No. 291, GIDC Industrial Estate, Ankleshwar-393 002, Gujarat, India |
|
|
|
|
SEZ Unit: |
Plot No. 1 / 1A & 2, “PHARMEZ” (Special Economic Zone) Matoda, Sarkhej-Bavla N.H. No. 8A, Taluka : Sanand, District : Ahmedabad 382 213, Gujarat, India |
|
|
|
|
Zydus Research
Centre : |
Survey No. 396 / 403, Sarkhej-Bavla N.H. No. 8A, Moraiya, Ahmedabad 382 213, Gujarat, India |
|
|
|
|
Animal Health Unit
: |
Plot No. F-1/1, Sector 6B, IIE SIIDCUL, Haridwar-249403, Uttarakhand, India |
DIRECTORS
As on 31.03.2018
|
Name : |
Dr. Sharvil Pankajbhai Patel |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Managing Director |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
16, Azad Society, Ambawadi, Ahmedabad –
380015, Gujarat, India |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of
Birth/Age : |
13.10.1978 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of
Appointment : |
01.08.1997 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DIN No.: |
00131995 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other Directorship:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Name : |
Mr. Ganesh Narayan Nayak |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Whole-time Director |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
3, Ashwamegh, Part V, Satellite, Ahmedabad-380015, Gujarat, India |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of
Birth/Age : |
16.03.1953 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of
Appointment : |
12.07.2017 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DIN No.: |
00017481 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other
Directorship:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Name : |
Mr. Pankaj Ramanbhai Patel |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Director |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
16, Azad Society, Ambawadi, Ahmedabad –
380015, Gujarat, India |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of
Birth/Age : |
16.03.1953 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of
Appointment : |
15.05.1995 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DIN No.: |
00131852 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other
Directorship:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Name : |
Mr. Humayun Dhanrajgiri |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Director |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
F 37/38, Dhanraj Mahal, CSM Road, Apollo Bunder, Mumbai-400039,
Maharashtra, India |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of
Birth/Age : |
02.12.1936 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of
Appointment : |
16.08.2003 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DIN No.: |
00004006 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other
Directorship:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Name : |
Mr. Mukesh Mangalbhai Patel |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Director |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
"Prakruti", 11, Ashwamegh Bunglow, Part- II Satellite Road,
Ahmedabad- 380015, Gujarat, India |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of
Birth/Age : |
22.01.1954 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of
Appointment : |
01.08.1997 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DIN No.: |
00053892 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other
Directorship:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Name : |
Mr. Nitin Raojibhai Desai |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Director |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
457, Sind Housing Society, Aundh, Pune-411007, Maharashtra, India |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of
Birth/Age : |
01.11.1943 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of
Appointment : |
06.05.2011 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DIN No.: |
00140239 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other
Directorship:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Name : |
Mr. Apurva Shishir Diwanji |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Director |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
Wyoming Building, 5th Floor, 12-A Little Gibbs Road, Malbar Hill,
Mumbai -400006, Maharashtra, India |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of
Birth/Age : |
17.01.1969 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of
Appointment : |
13.05.2016 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DIN No.: |
00032072 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other
Directorship:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Name : |
Mrs. Dharmishta Narendraprasad Rawal |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Director |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
25, Saurabh Society Drive In Road, Ahmedabad-380009, Gujarat, India |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of
Birth/Age : |
12.01.1956 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of
Appointment : |
16.05.2014 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DIN No.: |
02792246 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other
Directorship:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note: Designation of the directors has been updated as per the latest government registry.
KEY EXECUTIVES
|
Name |
Mr. Upenkumar Harshadlal Shah |
|
Designation |
Company Secretary |
|
Address: |
A/306, Swastik Residency, 2, Opera Society Vikas Gruh Road, Paldi Ahmedabad- 380007, Gujarat, India |
|
Date of Appointment
: |
01.01.2003 |
|
PAN No: |
AGSPS7342D |
|
|
|
|
Name |
Mr. Nitinkumar Dalsukhray Parekh |
|
Designation |
Chief Financial Officer |
|
Address: |
A-3, Aryaman Bungalows, Near Railway Crossing, Thaltej - Shilaj Road, Ahmedabad – 380059, Gujarat, India |
|
Date of Appointment
: |
10.02.2015 |
|
PAN No: |
AAMPP6584E |
MAJOR SHAREHOLDERS
As on March, 2018
|
Category of shareholder |
No. of fully paid up equity shares held |
Shareholding as a % of total no. of
shares (calculated as per SCRR, 1957)As a % of (A+B+C2) |
|
|
(A) Promoter & Promoter
Group |
765690230 |
74.79 |
|
|
(B) Public |
258052370 |
25.21 |
|
|
Grand Total |
1023742600 |
100.00 |
Statement showing shareholding pattern of the Promoter and
Promoter Group
|
Category of shareholder |
No. of fully paid up equity shares held |
Shareholding as a % of total no. of
shares (calculated as per SCRR, 1957)As a % of |
|
|
A1) Indian |
|||
|
Individuals/Hindu
undivided Family |
135000 |
0.01 |
|
|
Pankaj Ramanbhai Patel |
45000 |
0.00 |
|
|
Pankaj Ramanbhai Patel HUF |
30000 |
0.00 |
|
|
Pankaj R. Patel – Trustee of
Taraben Patel Family Will Trust |
15000 |
0.00 |
|
|
Sharil Patel |
15000 |
0.00 |
|
|
Pritiben P. Patel |
15000 |
0.00 |
|
|
Shivani P. Patel |
15000 |
0.00 |
|
|
Any
Other (specify) |
765555230 |
74.78 |
|
|
Zydus Family Trust |
765537230 |
74.78 |
|
|
Pripan Investment Private
Limited |
18000 |
0.00 |
|
|
Sub
Total A1 |
765690230 |
74.79 |
|
|
A2) Foreign |
0.00 |
||
|
A=A1+A2 |
765690230 |
74.79 |
Statement showing shareholding pattern of the Public
shareholder
|
Category & Name of the Shareholders |
No. of fully paid up equity shares held |
Shareholding % calculated as per SCRR,
1957 As a % |
|
|
B1)
Institutions |
|
|
|
|
Mutual
Funds/ |
44925607 |
4.39 |
|
|
Franklin Templeton Mutual Fund
A/C Franklin India Prima Plus |
15044247 |
1.47 |
|
|
Alternate
Investment Funds |
142605 |
0.01 |
|
|
Foreign
Portfolio Investors |
89048796 |
8.70 |
|
|
GOVERNMENT PENSION GLOBAL
SCHEME |
10900598 |
1.06 |
|
|
Financial
Institutions/ Banks |
36199525 |
3.54 |
|
|
LIFE INSURANCE CORPORATION OF
INDIA |
28768606 |
2.81 |
|
|
Sub
Total B1 |
170316533 |
16.64 |
|
|
B2)
Central Government/ State Government(s)/ President of India |
0 |
0.00 |
|
|
Central
Government/ State Government(s)/ President of India |
1702409 |
0.17 |
|
|
Sub
Total B2 |
1702409 |
0.17 |
|
|
B3)
Non-Institutions |
0 |
0.00 |
|
|
Individual
share capital upto INR 0.200 million |
43134274 |
4.21 |
|
|
Individual
share capital in excess of INR 0.200 million |
9275626 |
0.91 |
|
|
Any
Other (specify) |
33623528 |
3.28 |
|
|
Trusts |
361433 |
0.04 |
|
|
HUF |
1719197 |
0.17 |
|
|
Non-Resident Indian (NRI) |
2131864 |
0.21 |
|
|
Overseas Corporate Bodies |
1305 |
0.00 |
|
|
Clearing Members |
634234 |
0.06 |
|
|
Bodies Corporate |
28775495 |
2.81 |
|
|
Sub
Total B3 |
86033428 |
8.40 |
|
|
B=B1+B2+B3 |
258052370 |
25.21 |
BUSINESS DETAILS
|
Line of Business : |
Subject operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. (Registered Activity) Line of business is updated as per latest annual report 2017 |
||||
|
|
|
||||
|
Products / Services
: |
|
||||
|
|
|
||||
|
Brand Names : |
Not Divulged |
||||
|
|
|
||||
|
Agencies Held : |
Not Divulged |
||||
|
|
|
||||
|
Exports : |
Not Divulged |
||||
|
|
|
||||
|
Imports : |
Not Divulged |
||||
|
|
|
||||
|
Terms : |
Not Divulged |
PRODUCTION STATUS – (NOT AVAILABLE)
GENERAL INFORMATION
|
Suppliers : |
|
||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
|
Customers : |
|
||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
|
No. of Employees
(As on 31.03.2017) : |
16885 (Approximately) Note : As per latest annual report there is an increase in the number of employees over past years and current number employees are 16885 |
||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
|
Bankers (As on 2017) : |
·
The Bank of Tokyo-Mitsubishi UFJ Limited, 9
Raffles Place# 01-01 Republic Plaza Singapore NA 048619 · Citi Bank N.A., Citibank Building 110, Thompson Boulevard, Nassu Bahmas NA 0 BS |
||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
|
Facilities : |
|
||||||||||||||||||||||||
|
Auditors : |
|
|
Name : |
Mukesh M. Shah and Company Chartered Accountants |
|
Address : |
7th Floor, Heritage Chambers, Behind Bikanerwala, Off. S.M. Road, Near Azad Society, Nehru Nagar, Ahmedabad – 380015, Gujarat, India |
|
Tel. No.: |
91-79-26472000 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Memberships : |
Not Available |
|
|
|
|
Collaborators : |
Not Available |
|
|
|
|
Subsidiary
Companies/ concerns (As on 31.03.2017) : |
· Dialforhealth India Limited · Zydus Pharmaceuticals (USA) Inc. [USA] · Dialforhealth Unity Limited · Dialforhealth Greencross Limited · Zydus Healthcare (USA) LLC [USA] · Zydus Healthcare Limited · Sentynl Therapeutics Inc. [USA] · Zydus Wellness Limited Zydus Noveltech Inc. [USA] · Zydus Wellness-Sikkim, a Partnership Firm · Hercon Pharmaceuticals LLC [USA] · Liva Pharmaceuticals Limited Zydus Healthcare S.A. (Pty) Limited [South Africa] · Zydus Technologies Limited · Simayla Pharmaceuticals (Pty) Limited [South Africa] · Biochem Pharmaceutical Industries Limited · Script Management Services (Pty) Limited [South Africa] · Alidac Pharmaceuticals Limited Zydus France, SAS [France] · Zydus Lanka (Private) Limited [Sri Lanka] · Zydus Nikkho Farmaceutica Ltda. [Brazil] · Zydus Healthcare Philippines Inc. [Philippines] · Zydus Pharma Japan Company Limited [Japan] [Liquidated during the year] · Zydus International Private Limited [Ireland] · Laboratorios Combix S.L. [Spain] · Zydus Netherlands B.V. [the Netherlands] · Zydus Pharmaceuticals Mexico SA De CV [Mexico] · ZAHL B.V. [the Netherlands] · Zydus Pharmaceuticals Mexico Services Company SA De C.V. [Mexico] · ZAHL Europe B.V. [the Netherlands] · Etna Biotech S.R.L. [Italy] · Bremer Pharma GmbH [Germany] · Zydus Worldwide DMCC [Dubai] · Alidac Healthcare (Myanmar) Limited [Myanmar] ·
Zydus Discovery DMCC [Dubai] |
|
|
|
|
Joint Venture
Companies (As on 31.03.2017) : |
· Zydus Hospira Oncology Private Limited · Bayer Zydus Pharma Private Limited · Zydus Takeda Healthcare Private Limited |
|
|
|
|
Enterprises
significantly influenced by Directors and/or their relatives (As on
31.03.2017) : |
· Cadmach Machinery Company Private Limited · Western Ahmedabad Effluent Conveyance Company Private Limited · Zydus Hospitals and Healthcare Research Private Limited · Zandra Infrastructure LLP · Zydus Hospitals (Vadodra) Private Limited · Zydus Hospital LLP Zydus Hospitals (Rajkot) Private Limited · C. M. C. Machinery MabS Biotech Private Limited · Cadam Enterprises Zydus Infrastructure Private Limited · Mukesh M. Patel and Company · Cadila Laboratories Private Limited · International Tax and Investments Consultants · Pripan Investment Private Limited · Zandra Herbs and Plantations LLP |
CAPITAL STRUCTURE
As on 31.03.2018
Authorised Capital : NOT AVAILABLE
Issued, Subscribed & Paid-up Capital : INR 1024.000 Million
As on 31.03.2017
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
1725000000 |
Equity Shares |
INR 1/- each |
INR 1725.000 Million |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
1023742600 |
Equity Shares |
INR 1/- each |
INR 1024.000 Million |
|
|
|
|
|
The reconciliation in
number of shares is as under: Number of shares at the beginning of the year
|
Particulars |
As at March 31, 2017 |
|
Number of shares at the beginning of the year |
1023742600 |
|
Add: Issued pursuant to sub-division of face value of the shares from INR 5/- each to INR 1/- each * |
-- |
|
Number of shares at
the end of the year |
1023742600 |
The Company has only one class of equity shares having a par value of INR 1/- per share. Each holder of equity share is entitled to one vote per share. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the Annual General Meeting, except in the case of interim dividend. In the event of liquidation of the Company, the equity shareholders shall be entitled to proportionate share of their holding in the assets remaining after distribution of all preferential amounts.
Details of Shareholder holding more than 5% of aggregate Equity Shares of INR 1/- each [as at March 31, 2016: INR 1/- (as at April 1, 2015: INR 5/-) each], fully paid:
|
Name of Shareholders |
As at March 31, 2017 |
|
|
Number of Shares |
% to total share holding |
|
|
Zydus Family Trust |
765537230 |
74.78% |
|
|
|
|
* During the previous year, the face value of the equity shares had been sub-divided from INR 5/- each to INR 1/- each per equity share with effect from October 7, 2015, pursuant to the approval of the members through postal ballot process. Accordingly, number of equity shares under the Authorised, Issued, Subscribed and Paid-up capital had been increased.
LISTING DETAILS:
|
BSE : 532321 NSE : CADILAHC ISIN : INE010B01027 |
|
|
Stock Exchange
Place : |
BSE Limited [BSE] The National Stock Exchange of India Limited [NSE] |
|
Listed Date : |
NA |
FINANCIAL DATA
[all figures are
INR Million]
ABRIDGED
BALANCE SHEET (STANDALONE)
|
SOURCES
OF FUNDS |
31.03.2018 |
31.03.2017 |
31.03.2016 |
|
|
|
|
|
|
I.
EQUITY AND LIABILITIES |
|
|
|
|
(1)Shareholders' Funds |
|
|
|
|
(a) Share Capital |
1024.000 |
1024.000 |
1024.000 |
|
(b) Reserves & Surplus |
76431.000 |
65159.000 |
60350.000 |
|
(c) Money received against
share warrants |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
(2) Share Application money
pending allotment |
0.000 |
0.000 |
0.000 |
|
Total
Shareholders’ Funds (1) + (2) |
77455.000 |
66183.000 |
61374.000 |
|
|
|
|
|
|
(3) Non-Current Liabilities |
|
|
|
|
(a) long-term borrowings |
13009.000 |
12394.000 |
4300.000 |
|
(b) Deferred tax liabilities
(Net) |
9921.000 |
1055.000 |
1521.000 |
|
(c) Other long term
liabilities |
4694.000 |
82.000 |
167.000 |
|
(d) long-term provisions |
283.000 |
621.000 |
965.000 |
|
Total
Non-current Liabilities (3) |
27907.000 |
14152.000 |
6953.000 |
|
|
|
|
|
|
(4) Current Liabilities |
|
|
|
|
(a) Short term borrowings |
13009.000 |
15456.000 |
6043.000 |
|
(b) Trade payables |
9921.000 |
11129.000 |
8982.000 |
|
(c) Other current liabilities |
4694.000 |
3281.000 |
3629.000 |
|
(d) Short-term provisions |
283.000 |
273.000 |
549.000 |
|
Total
Current Liabilities (4) |
27907.000 |
30139.000 |
19203.000 |
|
|
|
|
|
|
TOTAL |
121637.000 |
110474.000 |
87530.000 |
|
|
|
|
|
|
II.
ASSETS |
|
|
|
|
(1) Non-current assets |
|
|
|
|
(a) Fixed Assets |
|
|
|
|
(i) Tangible assets |
25454.000 |
22050.000 |
19997.000 |
|
(ii) Intangible Assets |
1348.000 |
1470.000 |
1562.000 |
|
(iii) Capital work-in-progress |
6592.000 |
6784.000 |
2968.000 |
|
(iv) Intangible assets under
development |
0.000 |
0.000 |
0.000 |
|
(b) Non-current Investments |
36181.000 |
39237.000 |
20122.000 |
|
(c) Deferred tax assets (net) |
0.000 |
0.000 |
0.000 |
|
(d) Long-term Loan and Advances |
13013.000 |
14271.000 |
13646.000 |
|
(e) Other Non-current assets |
3475.000 |
5268.000 |
0.000 |
|
Total
Non-Current Assets |
86063.000 |
89080.000 |
58295.000 |
|
|
|
|
|
|
(2) Current assets |
|
|
|
|
(a) Current investments |
0.000 |
0.000 |
1008.000 |
|
(b) Inventories |
13207.000 |
9329.000 |
6575.000 |
|
(c) Trade receivables |
12551.000 |
9290.000 |
17033.000 |
|
(d) Cash and cash equivalents |
1838.000 |
168.000 |
1633.000 |
|
(e) Short-term loans and
advances |
178.000 |
371.000 |
1804.000 |
|
(f) Other current assets |
7800.000 |
2236.000 |
1182.000 |
|
Total
Current Assets |
35574.000 |
21394.000 |
29235.000 |
|
|
|
|
|
|
TOTAL |
121637.000 |
110474.000 |
87530.000 |
PROFIT
& LOSS ACCOUNT (STANDALONE)
|
|
PARTICULARS |
|
31.03.2018 |
31.03.2017 |
|
|
SALES |
|
|
|
|
|
Income |
|
58099.000 |
32307.000 |
|
|
Other Income |
|
2079.000 |
5831.000 |
|
|
TOTAL
|
|
60178.000 |
38138.000 |
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
Cost of Materials Consumed |
|
15640.000 |
9267.000 |
|
|
Purchases of Stock-in-Trade |
|
3186.000 |
2288.000 |
|
|
Changes in inventories of finished
goods, work-in-progress and Stock-in-Trade |
|
(1869.000) |
(1470.000) |
|
|
Employees benefits expense |
|
8260.000 |
6208.000 |
|
|
Other expenses |
|
16419.000 |
12803.000 |
|
|
TOTAL |
|
41636.000 |
29096.000 |
|
|
|
|
|
|
|
|
PROFIT/
(LOSS) BEFORE INTEREST, TAX,
DEPRECIATION AND AMORTISATION |
|
18542.000 |
9042.000 |
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES |
|
639.000 |
111.000 |
|
|
|
|
|
|
|
|
PROFIT
/ (LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION |
|
17903.000 |
8931.000 |
|
|
|
|
|
|
|
Less/
Add |
DEPRECIATION/
AMORTISATION |
|
2931.000 |
2509.000 |
|
|
|
|
|
|
|
|
PROFIT/
(LOSS) BEFORE TAX |
|
14972.000 |
6422.000 |
|
|
|
|
|
|
|
Less |
TAX |
|
4064.000 |
(197.000) |
|
|
|
|
|
|
|
|
PROFIT/
(LOSS) AFTER TAX |
|
10908.000 |
6619.000 |
|
|
|
|
|
|
|
|
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
|
47315.000 |
44072.000 |
|
|
|
|
|
|
|
|
Items of other Comprehensive
income recognised directly in Retained Earnings: Re-measurement gains/
[losses] on defined benefit plans [net of tax] |
|
NA |
81.000 |
|
|
|
|
|
|
|
|
Additional depreciation upon revision in useful lives of tangible
assets |
|
NA |
0.000 |
|
|
|
|
|
|
|
Less
|
APPROPRIATIONS |
|
|
|
|
|
Dividends |
|
NA |
3276.000 |
|
|
Corporate Dividend Tax
on Dividend |
|
NA |
19.000 |
|
|
Total |
|
NA |
3295.000 |
|
|
|
|
|
|
|
|
Balance
Carried to the B/S |
|
NA |
47315.000 |
|
|
|
|
|
|
|
|
EARNINGS IN FOREIGN
CURRENCY |
|
|
|
|
|
F.O.B. Value of Exports |
|
NA |
21280.000 |
|
|
TOTAL EARNINGS |
|
NA |
21280.000 |
|
|
|
|
|
|
|
|
Earnings
/ (Loss) Per Share (INR) |
|
10.66 |
6.47 |
|
|
PARTICULARS |
|
|
31.03.2016 |
|
|
SALES |
|
|
|
|
|
Income |
|
|
70353.000 |
|
|
Other Income |
|
|
1341.000 |
|
|
TOTAL |
|
|
71694.000 |
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
Cost of Materials
Consumed |
|
|
13320.000 |
|
|
Purchases of
Stock-in-Trade |
|
|
5096.000 |
|
|
Changes in inventories of
finished goods, work-in-progress and Stock-in-Trade |
|
|
502.000 |
|
|
Employees benefits
expense |
|
|
7174.000 |
|
|
Other expenses |
|
|
18831.000 |
|
|
TOTAL |
|
|
44923.000 |
|
|
|
|
|
|
|
Less |
PROFIT/ (LOSS) BEFORE INTEREST, TAX, DEPRECIATION AND
AMORTISATION |
|
|
26771.000 |
|
|
|
|
|
|
|
Less |
FINANCIAL EXPENSES |
|
|
224.000 |
|
|
|
|
|
|
|
|
PROFIT / (LOSS) BEFORE
TAX, DEPRECIATION AND AMORTISATION |
|
|
26547.000 |
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION |
|
|
2212.000 |
|
|
|
|
|
|
|
|
PROFIT/ (LOSS) BEFORE TAX |
|
|
24335.000 |
|
|
|
|
|
|
|
Less |
TAX |
|
|
4562.000 |
|
|
|
|
|
|
|
|
PROFIT/ (LOSS) AFTER TAX |
|
|
19773.000 |
|
|
|
|
|
|
|
Less |
APPROPRIATIONS |
|
|
|
|
|
Transfer to General
Reserve |
|
|
0.000 |
|
|
Dividend |
|
|
0.000 |
|
|
Transfer to Debenture
Redemption Reserve |
|
|
0.000 |
|
|
Interim Dividend |
|
|
3276.000 |
|
|
Tax on Dividend |
|
|
608.000 |
|
|
Total |
|
|
3884.000 |
|
|
|
|
|
|
|
|
Balance Carried to the
B/S |
|
|
15889.000 |
|
|
|
|
|
|
|
|
EARNINGS IN FOREIGN
CURRENCY |
|
|
|
|
|
F.O.B. Value of Exports |
|
|
44537.000 |
|
|
Royalty |
|
|
37.000 |
|
|
Others |
|
|
2293.000 |
|
|
Interest |
|
|
165.000 |
|
|
Professional and
Consultation Fees |
|
|
736.000 |
|
|
TOTAL EARNINGS |
|
|
47768.000 |
|
|
|
|
|
|
|
|
IMPORTS |
|
|
|
|
|
Raw Materials |
|
|
2916.000 |
|
|
Packing Materials |
|
|
391.000 |
|
|
Finished goods |
|
|
390.000 |
|
|
Components and Stores
parts |
|
|
782.000 |
|
|
Capital Goods |
|
|
1359.000 |
|
|
TOTAL IMPORTS |
|
|
5838.000 |
|
|
|
|
|
|
|
|
Earnings / (Loss) Per
Share (INR) |
|
|
19.31 |
CURRENT MATURITIES
OF LONG TERM DEBT DETAILS
|
Particulars |
31.03.2018 |
31.03.2017 |
31.03.2016 |
|
Current Maturities of Long term debt |
NA |
2619.000 |
1885.000 |
|
Cash generated from operations |
NA |
13997.000 |
23103.000 |
|
Net cash from operating activities |
NA |
12919.000 |
19188.000 |
KEY
RATIOS
EFFICIENCY RATIOS
|
PARTICULARS |
31.03.2018 |
31.03.2017 |
31.03.2016 |
|
Average Collection Days (Sundry Debtors / Income * 365 Days) |
78.85 |
104.96 |
88.37 |
|
|
|
|
|
|
Account Receivables Turnover (Income / Sundry
Debtors) |
4.63 |
3.48 |
4.13 |
|
|
|
|
|
|
Average Payment Days (Sundry Creditors
/ Purchases * 365 Days) |
192.35 |
351.54 |
178.02 |
|
|
|
|
|
|
Inventory Turnover (Operating Income
/ Inventories) |
1.40 |
0.97 |
4.07 |
|
|
|
|
|
|
Asset Turnover (Operating Income
/ Net Fixed Assets) |
0.56 |
0.30 |
1.09 |
LEVERAGE RATIOS
|
PARTICULARS |
31.03.2018 |
31.03.2017 |
31.03.2016 |
|
Debt Ratio ((Borrowing + Current Liabilities) / Total
Assets) |
0.34 |
0.41 |
0.29 |
|
|
|
|
|
|
Debt Equity Ratio (Total Liability
/ Networth) |
0.34 |
0.46 |
0.20 |
|
|
|
|
|
|
Current Liabilities to Networth (Current
Liabilities / Net Worth) |
0.36 |
0.46 |
0.31 |
|
|
|
|
|
|
Fixed Assets to Networth (Net Fixed Assets
/ Networth) |
0.43 |
0.46 |
0.40 |
|
|
|
|
|
|
Interest Coverage Ratio (PBIT / Financial
Charges) |
29.02 |
81.46 |
119.51 |
PROFITABILITY RATIOS
|
PARTICULARS |
|
31.03.2018 |
31.03.2017 |
31.03.2016 |
|
Net Profit Margin ((PAT / Sales) *
100) |
% |
18.77 |
20.49 |
28.11 |
|
|
|
|
|
|
|
Return on Total Assets ((PAT / Total Assets)
* 100) |
% |
8.97 |
5.99 |
22.59 |
|
|
|
|
|
|
|
Return on Investment (ROI) ((PAT / Networth)
* 100) |
% |
14.08 |
10.00 |
32.22 |
SOLVENCY RATIOS
|
PARTICULARS |
31.03.2018 |
31.03.2017 |
31.03.2016 |
|
Current Ratio (Current Assets / Current Liabilities) |
1.27 |
0.71 |
1.52 |
|
|
|
|
|
|
Quick Ratio ((Current Assets
– Inventories) / Current Liabilities) |
0.80 |
0.40 |
1.18 |
|
|
|
|
|
|
G-Score Ratio Financial (Networth / Total
Assets) |
0.64 |
0.60 |
0.70 |
|
|
|
|
|
|
G-Score Ratio Debt (Debts / Equity
Capital) |
25.90 |
29.75 |
11.94 |
|
|
|
|
|
|
G-Score Ratio Liquidity (Total Current
Assets / Total Current Liabilities) |
1.27 |
0.71 |
1.52 |
Total Liability = Short-term Debt + Long-term
Debt + Current Maturities of Long-term debts
STOCK
PRICES
|
Face Value |
INR 1.00 |
|
Market Value |
INR 367.00 |
FINANCIAL ANALYSIS
[all figures are
in INR Million]
DEBT EQUITY RATIO
|
Particular |
31.03.2016 |
31.03.2017 |
31.03.2018 |
|
|
INR In
Million |
INR
In Million |
INR
In Million |
|
Share Capital |
1024.000 |
1024.000 |
1024.000 |
|
Reserves & Surplus |
60350.000 |
65159.000 |
76431.000 |
|
Net
worth |
61374.000 |
66183.000 |
77455.000 |
|
|
|
|
|
|
long-term borrowings |
4300.000 |
12394.000 |
13511.000 |
|
Short term borrowings |
6043.000 |
15456.000 |
13009.000 |
|
Total
borrowings |
10343.000 |
27850.000 |
26520.000 |
|
Debt/Equity
ratio |
0.169 |
0.421 |
0.342 |
YEAR-ON-YEAR GROWTH
|
Year
on Year Growth |
31.03.2016 |
31.03.2017 |
31.03.2018 |
|
|
INR
In Million |
INR
In Million |
INR
In Million |
|
Sales |
70353.000 |
32307.000 |
58099.000 |
|
|
|
(54.079) |
79.834 |
NET PROFIT MARGIN
|
Net
Profit Margin |
31.03.2016 |
31.03.2017 |
31.03.2018 |
|
|
INR
In Million |
INR
In Million |
INR
In Million |
|
Sales |
70353.000 |
32307.000 |
58099.000 |
|
Profit |
19773.000 |
6619.000 |
10908.000 |
|
|
28.11% |
20.49% |
18.77% |
ABRIDGED
BALANCE SHEET (CONSOLIDATED)
|
SOURCES OF FUNDS |
|
31.03.2018 |
31.03.2017 |
|
|
|
|
|
|
I.
EQUITY AND LIABILITIES |
|
|
|
|
(1)Shareholders' Funds |
|
|
|
|
(a) Share Capital |
|
1024.000 |
1024.000 |
|
(b) Reserves &
Surplus |
|
86421.000 |
68576.000 |
|
(c) Money received
against share warrants |
|
0.000 |
0.000 |
|
|
|
|
|
|
(2) Share Application money
pending allotment |
|
0.000 |
0.000 |
|
(3) Non-Controlling
Interests |
|
1910.000 |
1561.000 |
|
Total Shareholders’ Funds
|
|
89355.000 |
71161.000 |
|
|
|
|
|
|
(4) Non-Current
Liabilities |
|
|
|
|
(a) long-term borrowings |
|
25551.000 |
24684.000 |
|
(b) Deferred tax
liabilities (Net) |
|
2821.000 |
1164.000 |
|
(c) Other long term
liabilities |
|
537.000 |
628.000 |
|
(d) long-term provisions |
|
1559.000 |
1512.000 |
|
Total Non-current
Liabilities |
|
30468.000 |
27988.000 |
|
|
|
|
|
|
(5) Current Liabilities |
|
|
|
|
(a) Short term borrowings |
|
25575.000 |
24769.000 |
|
(b) Trade payables |
|
18884.000 |
16736.000 |
|
(c) Other current
liabilities |
|
15369.000 |
10980.000 |
|
(d) Short-term provisions |
|
1002.000 |
573.000 |
|
Total Current Liabilities
(4) |
|
60830.000 |
53058.000 |
|
|
|
|
|
|
TOTAL |
|
180653.000 |
152207.000 |
|
|
|
|
|
|
II.
ASSETS |
|
|
|
|
(1) Non-current assets |
|
|
|
|
(a) Fixed Assets |
|
|
|
|
(i) Tangible assets |
|
38157.000 |
32904.000 |
|
(ii) Intangible Assets |
|
26669.000 |
24647.000 |
|
(iii) Capital
work-in-progress |
|
15272.000 |
15433.000 |
|
(iv) Intangible assets
under development |
|
0.000 |
0.000 |
|
(b) Non-current
Investments |
|
4709.000 |
3857.000 |
|
(c) Deferred tax assets
(net) |
|
9246.000 |
5170.000 |
|
(d) Long-term Loan and Advances |
|
0.000 |
0.000 |
|
(e) Other Non-current
assets |
|
4303.000 |
9973.000 |
|
Total Non-Current Assets |
|
98356.000 |
91984.000 |
|
|
|
|
|
|
(2) Current assets |
|
|
|
|
(a) Current investments |
|
2748.000 |
491.000 |
|
(b) Inventories |
|
23853.000 |
18037.000 |
|
(c) Trade receivables |
|
32063.000 |
22775.000 |
|
(d) Cash and cash
equivalents |
|
13149.000 |
15435.000 |
|
(e) Short-term loans and
advances |
|
0.000 |
0.000 |
|
(f) Other current assets |
|
10484.000 |
3485.000 |
|
Total Current Assets |
|
82297.000 |
60223.000 |
|
|
|
|
|
|
TOTAL |
|
180653.000 |
152207.000 |
PROFIT
& LOSS ACCOUNT (CONSOLIDATED)
|
|
PARTICULARS |
|
31.03.2018 |
31.03.2017 |
|
|
SALES |
|
|
|
|
|
Income |
|
119049.000 |
94295.000 |
|
|
Other Income |
|
1132.000 |
1286.000 |
|
|
TOTAL |
|
120181.000 |
95581.000 |
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
Cost of Materials
Consumed |
|
25233.000 |
18310.000 |
|
|
Purchases of
Stock-in-Trade |
|
19141.000 |
17529.000 |
|
|
Changes in inventories of
finished goods, work-in-progress and Stock-in-Trade |
|
(3154.000) |
(1388.000) |
|
|
Employees benefits expense |
|
18545.000 |
15002.000 |
|
|
Other expenses |
|
30809.000 |
25806.000 |
|
|
Exceptional Items |
|
0.000 |
3.000 |
|
|
TOTAL |
|
90574.000 |
75262.000 |
|
|
|
|
|
|
|
|
PROFIT/ (LOSS) BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION
|
|
29607.000 |
20319.000 |
|
|
|
|
|
|
|
Less |
FINANCIAL EXPENSES |
|
911.000 |
450.000 |
|
|
|
|
|
|
|
|
PROFIT / (LOSS) BEFORE
TAX, DEPRECIATION AND AMORTISATION |
|
28696.000 |
19869.000 |
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION |
|
5388.000 |
3750.000 |
|
|
|
|
|
|
|
|
PROFIT/ (LOSS) BEFORE TAX |
|
23308.000 |
16119.000 |
|
|
|
|
|
|
|
Less |
TAX |
|
5644.000 |
1289.000 |
|
|
|
|
|
|
|
|
PROFIT/ (LOSS) AFTER TAX
|
|
17664.000 |
14830.000 |
|
|
|
|
|
|
|
Add |
SHARE OF PROFIT OF
JOINT VENTURES [NET OF TAX] |
|
628.000 |
338.000 |
|
|
|
|
|
|
|
Less |
NON-CONTROLLING
INTEREST |
|
346.000 |
0.000 |
|
|
|
|
|
|
|
|
PROFIT/ (LOSS) FOR THE
YEAR |
|
17946.000 |
15168.000 |
|
|
|
|
|
|
|
|
Earnings / (Loss) Per
Share (INR) |
|
17.35 |
14.82 |
LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check List by Info Agents |
Available in
Report (Yes / No) |
|
1] |
Year of establishment |
Yes |
|
2] |
Constitution of the entity Incorporation
details |
Yes |
|
3] |
Locality of the entity |
Yes |
|
4] |
Premises details |
No |
|
5] |
Buyer visit details |
-- |
|
6] |
Contact numbers |
Yes |
|
7] |
Name of the person contacted |
No |
|
8] |
Designation of contact person |
No |
|
9] |
Promoter’s background |
Yes |
|
10] |
Date of Birth of Proprietor / Partners /
Directors |
Yes |
|
11] |
Pan Card No. of Proprietor / Partners |
No |
|
12] |
Voter Id Card No. of Proprietor / Partners |
No |
|
13] |
Type of business |
Yes |
|
14] |
Line of Business |
Yes |
|
15] |
Export/import details (if applicable) |
No |
|
16] |
No. of employees |
No |
|
17] |
Details of sister concerns |
Yes |
|
18] |
Major suppliers |
No |
|
19] |
Major customers |
No |
|
20] |
Banking Details |
Yes |
|
21] |
Banking facility details |
Yes |
|
22] |
Conduct of the banking account |
-- |
|
23] |
Financials, if provided |
Yes |
|
24] |
Capital in the business |
Yes |
|
25] |
Last accounts filed at ROC, if applicable |
Yes |
|
26] |
Turnover of firm for last three years |
Yes |
|
27] |
Reasons for variation <> 20% |
-- |
|
28] |
Estimation for coming financial year |
No |
|
29] |
Profitability for last three years |
Yes |
|
30] |
Major shareholders, if available |
Yes |
|
31] |
External Agency Rating, if available |
Yes |
|
32] |
Litigations that the firm/promoter
involved in |
-- |
|
33] |
Market information |
-- |
|
34] |
Payments terms |
No |
|
35] |
Negative Reporting by Auditors in the
Annual Report |
No |
COMPANY OVERVIEW: (As
on 31.03.2017)
The Company a Company limited by shares, incorporated and
domiciled in India, operates as an integrated pharmaceutical company with
business encompassing the entire value chain in the research, development,
production, marketing and distribution of pharmaceutical products. The product
portfolio of the Company includes Active Pharmaceutical Ingredients [API],
animal health and veterinary and human formulations. The Company’s shares are
listed on the National Stock Exchange of India Limited [NSE] and BSE Limited.
The registered office of the Company is located at “Zydus Tower”, Satellite
Cross Roads, Sarkhej-Gandhinagar Highway, Ahmedabad - 380015.
UNSECURED LOAN
|
PARTICULARS |
31.03.2018 (INR
in Million) |
31.03.2017 (INR
in Million) |
|
Long-term
Borrowings |
|
|
|
Term Loans from
Banks |
|
|
|
External Commercial Borrowings in Foreign Currency |
NA |
11484.000 |
|
From Others |
NA |
45.000 |
|
Short-term borrowings |
|
|
|
Working Capital Loans from Banks |
NA |
7791.000 |
|
Total |
NA |
19320.000 |
INDEX
OF CHARGES
|
S No |
SRN |
Charge Id |
Charge Holder Name |
Date of Creation |
Date of Modification |
Date of Satisfaction |
Amount |
Address |
|
1 |
C74641796 |
10610473 |
Citi Bank N.A. |
24/12/2015 |
- |
- |
2250000000.0 |
CITIBANK BUILDING, 110, THOMSON BOULEVARD,NASSAUNA0BS |
|
2 |
G72990658 |
10504520 |
The Bank of Tokyo Mitsubishi UFJ Limited |
28/05/2014 |
27/12/2017 |
- |
1204040000.0 |
9, Raffles Place,# 01-01, Republic Plaza,Singapore NA 048619 SG |
|
3 |
G15439086 |
10396390 |
BANK OF BARODA |
21/12/2012 |
26/09/2016 |
- |
14500000000.0 |
ASHRAM ROAD BRANCH, VALLABH SADANOPP. NATRAJ CINEMA, ASHRAM ROAD AHMEDABAD GUJARAT 380009 INDIA |
|
4 |
G69364826 |
10516028 |
Citi Bank N.A. |
07/08/2014 |
- |
13/11/2017 |
930000000.0 |
Citibank Building 110, Thompson Boulevard, NassuBahmas NA0 BS |
|
5 |
G43430131 |
10430802 |
THE BANK OF TOKYO-MITSUBISHI UFJ LTD |
31/05/2013 |
- |
19/04/2017 |
1124860000.0 |
9 RAFFLES PLACE#01-01 REPUBLIC PLAZA SINGAPORE NA 048619 SG |
|
6 |
G02862118 |
10456406 |
BARCLAYS BANK PLC |
10/10/2013 |
- |
11/04/2016 |
1300000000.0 |
1 CHURCHILL PLACEE 14 5 HP LONDON NA1026167 GB |
|
7 |
C74677675 |
10332648 |
THE BANK OF NOVA SCOTIA ASIA LIMITED |
24/01/2012 |
- |
05/01/2016 |
1020000000.0 |
ONE REFFLES QUAY, # 20-01 NORTH TOWER SINGAPORE NA 048583 SG |
|
8 |
C62902473 |
10465522 |
Citi Bank N.A. |
21/11/2013 |
- |
25/08/2015 |
945000000.0 |
CITIBANK BUILDING,110 THOMSON BOULEVARDNASSUNA0BS |
|
9 |
C42893172 |
10323573 |
BANK OF AMERICA N.A. |
12/12/2011 |
- |
22/01/2015 |
384000000.0 |
1ST FLOOR,DLF CENTRE SANSAD MARG NEW DELHI 110001 INDIA |
|
10 |
C36456838 |
10201696 |
IDBI TRUSTEESHIP SERVICES LIMITED |
19/02/2010 |
- |
12/12/2014 |
500000000.0 |
Asian Bldg., Ground Floor, 17, R.Kamani Marg,Ballard Estate, MUMBAI MAHARASHTRA 400001 INDIA |
CONTINGENT
LIABILITIES:
|
PARTICULARS |
31.03.2018 (INR
in Million) |
31.03.2017 (INR
in Million) |
|
a. Claims against the Company not acknowledged as debts |
NA |
104.000 |
|
- Net of advance of |
NA |
4.000 |
|
- Includes in respect of Amalgamated {*} Companies |
NA |
2.000 |
|
b. i. In respect of guarantees given by Banks and/ or
counter guarantees given by the Company |
NA |
198.000 |
|
ii. In respect of corporate guarantees given by the Company
to Banks for the outstanding dues of loans availed by some of the subsidiary
companies |
NA |
21751.000 |
|
c. Other money for which the Company is contingently
liable: |
|
|
|
i. In respect of the demands raised by the Central Excise,
State Excise & Service Tax Authority |
NA |
348.000 |
|
- Net of advance of |
NA |
27.000 |
|
- Includes in respect of Amalgamated {*} Companies |
NA |
9.000 |
|
ii. In respect of the demands raised by the Ministry of
Chemicals & Fertilizers, Govt. of India under Drug Price Control Order,
1979/ 1995 for difference in actual price and price of respective bulk drug
allowed while fixing the price of certain formulations and disputed by the
Company, which the Company expect to succeed based on the legal advice |
NA |
68.000 |
|
- Net of advance of |
NA |
43.000 |
|
- Includes in respect of Amalgamated {*} Companies |
NA |
25.000 |
|
iii. In respect of Income Tax matters pending before appellate
authorities which the Company expects to succeed, based on decisions of
Tribunals/ Courts |
NA |
40.000 |
|
- Net of advance of |
NA |
16.000 |
|
iv. In respect of Sales Tax matters pending before appellate
authorities/ Court which the Company expects to succeed, based on decisions
of Tribunals/ Courts |
NA |
150.000 |
|
- Net of advance of |
NA |
37.000 |
|
v. Letters of Credit for Imports |
NA |
1.000 |
|
vi. The Company has imported certain capital equipment at
concessional rate of custom duty under “Export promotion of Capital Goods
Scheme” of the Central Government. The Company has undertaken an incremental
export obligation to the |
|
|
|
- extent of US $ Millions |
NA |
7.000 |
|
- equivalent to INR Millions approximately |
NA |
458.000 |
|
to be fulfilled during a specified period as applicable from the date of imports. The unprovided liability towards custom duty payable thereon in respect of unfulfilled export obligations |
NA |
76.000 |
FIXED ASSETS (As on 31.03.2017)
·
Freehold Land
·
Leasehold Land
·
Building
·
Plant and Equipments
· Furniture and Fixture
· Vehicles
·
Office Equipment
WEBSITE DETAILS
NEWS/ PRESS RELEASES
ZYDUS CADILA GETS
USFDA NOD FOR TIZANIDINE TABLETS
March 13, 2018
The approval by the
US Food and Drug Adminstration (USFDA) is for multiple strengths of 2 mg and 4
mg, the company said in a BSE filing.
Cadila Healthcare today said its group firm Zydus Cadila has received final approval from the US health regulator for its generic version of Tizanidine tablets used for treatment of muscle spasms.
The approval by the US Food and Drug Adminstration (USFDA) is for multiple strengths of 2 mg and 4 mg, the company said in a BSE filing.
The tablets will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad, the company added.
Tizanidine tablets are used to treat muscle spasms caused by certain conditions such as multiple sclerosis, spinal cord injury, it said.
The group has more than 180 approvals with over 320 abbreviated new drug approvals (ANDAs) filed since 2003-04, the company said.
CADILA HEALTHCARE Q3
BEATS ESTIMATES, PROFIT GROWS 68% DESPITE SIGNIFICANT RISE IN TAX COST
OPERATING PROFIT
DURING THE QUARTER SURGED 99.9 PERCENT TO INR 8412.000 MILLION AND MARGIN
EXPANDED BY 770 BASIS POINTS TO 25.8 PERCENT COMPARED TO YEAR-AGO
February 08, 2018
Cadila Healthcare has reported healthy growth of 67.7 percent year-on-year in consolidated net profit at INR 5433.000 Million despite significant rise in tax cost, driven by fantastic operational and revenue performance.
Profit for the year-ago period was at INR 3239.000 Million. The growth was also aided by other income which increased 148 percent YoY to INR 411.000 Million in Q3.
Consolidated revenue from operations shot up 41 percent to INR 32596.000 Million for quarter ended December 2017, compared to INR 23111.000 Million in corresponding quarter last fiscal.
Operating profit during the quarter surged 99.9 percent to INR 8412.000 Million and margin expanded by 770 basis points to 25.8 percent compared to year-ago.
Earnings beat analyst expectations. Profit was estimated at INR 5100.000 Million and operating income at INR 8090.000 Million with margin at 25 percent for the quarter, according to average of estimates of analysts polled by CNBC-TV18.
Tax expenses for the quarter stood at INR 1786.000 Million, which increased sharply compared to INR 81.000 Million in same period last year.
During the quarter, the company received approval for 24 new products for the US market and filed 10 additional abbreviated new drug applications (ANDAs) with the USFDA.
It launched 2 new products in the US in Q3 while in India, it launched 12 new products.
March 08, 2018
Zydus partners
Medicure to launch cholesterol drug in US
"The launch of
ZYPITAMAG, which is used to manage cholesterol levels, marks the first branded
product launch for Zydus in the US," the company said in a regulatory
filing.
Drug firm Zydus Cadila has entered into a definitive agreement with US-based Medicure International Inc to commercialise its new drug application product pitavastatin magnesium in the US.
"The launch of ZYPITAMAG, which is used to manage cholesterol levels, marks the first branded product launch for Zydus in the US," the company said in a regulatory filing.
Zydus Cadila said as part of this agreement, it will hold the new drug application (NDA) and Medicure will be responsible for the sales and marketing of ZYPITAMAG.
Zydus Cadila has entered into an agreement with Medicure International Inc., a subsidiary of Medicure Inc.
ZYPITAMAG has been approved in strengths of 1 mg, 2 mg and 4 mg.
May 28, 2018
ZYDUS CADILA GETS
USFDA NOD FOR SKIN OINTMENT, STOMACH AILMENT DRUG
Zydus Cadila has
received the final approval from the United States Food and Drug Administration
(USFDA) to market Nystatin Ointment USP, 100,000 units per gram, the company
said in a BSE filing.
Zydus Cadila has received final approval from the US health regulator to market Nystatin ointment and Omeprazoleand Sodium Bicarbonate capsules.
Nystatin ointment is used to treat fungal skin infections.
Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Nystatin Ointment USP, 100,000 units per gram, the company said in a BSE filing.
Zydus Cadila said the drug will be produced at the group's Topical manufacturing facility at Moraiya, Ahmedabad.
The group has also received final approval to market Omeprazoleand Sodium Bicarbonate Capsules, 20 mg/1100 mg and 40 mg/1100 mg, used to treat certain stomach and esophagus problems (such as acid reflux, ulcers).
The group has more than 190 approvals, and so far filed over 320 abbreviated new drug applications (ANDAs) since it started filings in 2003-04.
Shares of Cadila Healthcare, the listed entity of the group, were trading 4.34 down per cent at INR 365.90 per scrip on BSE.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts, India Prisons Service,
Interpol, etc.
1] INFORMATION ON DESIGNATED
PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on Corporate
Governance to identify management and governance. These factors often have been
predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
INR |
|
US Dollar |
1 |
INR 67.63 |
|
UK Pound |
1 |
INR 89.70 |
|
Euro |
1 |
INR 78.20 |
INFORMATION DETAILS
|
Information
Gathered by : |
SHT |
|
|
|
|
Analysis Done by
: |
DIV |
|
|
|
|
Report Prepared
by : |
JYTK |
SCORE FACTORS
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
YES |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.